PPP3CA: IHC Expression in Cancer and Radioligand Target Profile
PPP3CA, protein phosphatase 3 catalytic subunit alpha, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PPP3CA staining is highest in thyroid cancer (100% of samples positive), prostate cancer (100% of samples positive) and head and neck cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).
Is PPP3CA the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze PPP3CA freeIs PPP3CA a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PPP3CA IHC staining by cancer type
Protein expression of PPP3CA across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.67 | High | 100% |
| Prostate Cancer | 0.63 | High | 100% |
| Head and Neck Cancer | 0.58 | High | 100% |
| Lymphoma | 0.44 | Medium | 75% |
| Bladder Cancer | 0.39 | Medium | 83% |
| Pancreatic Cancer | 0.36 | Medium | 64% |
| Kidney Cancer | 0.36 | Medium | 75% |
| Neuroendocrine Tumors | 0.33 | Medium | 75% |
| Glioma | 0.31 | Medium | 58% |
| Ovarian Cancer | 0.28 | Medium | 67% |
| Breast Cancer | 0.27 | Medium | 64% |
| Cervical Cancer | 0.27 | Medium | 55% |
| Skin Cancer | 0.24 | Medium | 55% |
| Endometrial Cancer | 0.19 | Low | 42% |
| Lung Cancer | 0.17 | Low | 42% |
| Colorectal Cancer | 0.15 | Low | 46% |
| Gastric Cancer | 0.13 | Low | 40% |
| Melanoma | 0.08 | Low | 25% |
| Testicular Cancer | 0.08 | Low | 25% |
| Liver Cancer | 0.08 | Low | 17% |
Is PPP3CA internalized?
Nuclens has not yet extracted internalization evidence for PPP3CA. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
PPP3CA clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for PPP3CA yet. Search ClinicalTrials.gov for PPP3CA trials.
PPP3CA normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PPP3CA in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PPP3CA gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · SSTR2 · EPCAM · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how PPP3CA ranks against 15,000 targets for your indication.
Analyze PPP3CA freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.